New pill could clear psoriasis in weeks
NCT ID NCT07234591
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests an experimental oral drug called a TYK2 inhibitor for people with moderate to severe plaque psoriasis. About 140 adults will receive either the drug or a placebo for 12 weeks. The main goal is to see if the drug can reduce psoriasis severity by at least 75%.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TYK2 inhibitor
- What this could lead to
- If it works, this could provide a new oral treatment option for people with moderate to severe plaque psoriasis.
- What could go wrong
- This is an early-stage trial with only 140 participants, so results may not apply to everyone. The drug may not work better than placebo or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MODERATE TO SEVERE PLAQUE PSORIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Skin Disease Hospital
RECRUITINGShanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Once-Weekly pill clear stubborn psoriasis?
- Can a new injection clear psoriasis when other biologics fail?
- Can a gel tame psoriasis? new antibody fragment put to the test
- Can a Once-Daily cream tame psoriasis in toddlers?
- Can a new drug called ZP9830 calm psoriasis Flare-Ups?
- Can we predict psoriasis relapse after biologics? a new study digs into the clues.